{"filing":{"accession_number":"0001193125-26-350349","cik":"0001885522","ticker":"NMRA","company_name":"Neumora Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-14","report_date":"2026-08-14","primary_document":"nmra-20260814.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885522/000119312526350349/nmra-20260814.htm"},"events":[{"id":27721,"run_id":25297,"accession_number":"0001193125-26-350349","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Neumora disclosed second quarter 2026 financial results, including R\u0026D expenses of $29.3M, G\u0026A expenses of $12.9M, net loss of $43.1M, and cash position of $116.8M, with forward-looking guidance on cash runway through Q3 2027.","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29376,"accession_number":"0001193125-26-350349","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Neumora's second quarter 2026 financial results, including R\u0026D expenses ($29.3M), G\u0026A expenses ($12.9M), net loss ($43.1M), and cash position ($116.8M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes comparative financial data and forward-looking guidance on cash runway through Q3 2027, making it material to investors assessing the company's financial condition and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:14:02.786824+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":27722,"run_id":25297,"accession_number":"0001193125-26-350349","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Joshua Pinto, Ph.D., was appointed Chief Executive Officer effective August 14, 2026, and also appointed as a Class III director, succeeding Paul L. Berns who transitioned to Executive Chairperson.","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-08-14","form":"8-K","submitted_at":null,"items":[{"id":29377,"accession_number":"0001193125-26-350349","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Joshua Pinto, Ph.D., the Company's current President, was appointed Chief Executive Officer effective August 14, 2026, and also appointed as a Class III director. While Paul L. Berns transitioned from CEO to Executive Chairperson, the principal disclosed action centers on Dr. Pinto's appointment to the CEO role and the Board, making this an executive appointment event. The filing explicitly states the Board approved \"the appointment of Dr. Pinto as a Class III director\" and his succession as CEO, which are the material leadership changes announced.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:14:02.786824+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29376,"accession_number":"0001193125-26-350349","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Neumora's second quarter 2026 financial results, including R\u0026D expenses ($29.3M), G\u0026A expenses ($12.9M), net loss ($43.1M), and cash position ($116.8M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes comparative financial data and forward-looking guidance on cash runway through Q3 2027, making it material to investors assessing the company's financial condition and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:14:02.786824+00:00","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-08-14"},{"id":29377,"accession_number":"0001193125-26-350349","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Joshua Pinto, Ph.D., the Company's current President, was appointed Chief Executive Officer effective August 14, 2026, and also appointed as a Class III director. While Paul L. Berns transitioned from CEO to Executive Chairperson, the principal disclosed action centers on Dr. Pinto's appointment to the CEO role and the Board, making this an executive appointment event. The filing explicitly states the Board approved \"the appointment of Dr. Pinto as a Class III director\" and his succession as CEO, which are the material leadership changes announced.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T11:14:02.786824+00:00","company_name":"Neumora Therapeutics, Inc.","ticker":"NMRA","filing_date":"2026-08-14"}]}